The effects of single-dose dexamethasone on inflammatory response and pain after uterine artery embolisation for symptomatic fibroids or adenomyosis: a randomised controlled study
RCT
OA: green
CC0
⤵ 4 in-corpus citations
AI-generated summary
Single-dose intravenous dexamethasone administered before uterine artery embolisation reduced inflammatory markers, pain, nausea, and vomiting in patients with fibroids or adenomyosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To investigate the effects of single-dose intravenous dexamethasone on inflammatory responses, pain, nausea, and vomiting after uterine artery embolisation (UAE).
DESIGN: Prospective, randomised, double-blind, and placebo-controlled study.
SETTING: Tertiary-care University centre in Korea.
POPULATION: Patients undergoing UAE for the treatment of symptomatic fibroids or adenomyosis.
METHODS: Patients were randomised to receive either intravenous dexamethasone (10 mg; dexamethasone group) or normal saline (control group) 1 hour before UAE. Both groups received fentanyl-based intravenous patient-controlled analgesia (PCA) during the 24 hours after UAE.
MAIN OUTCOME MEASURES: The primary outcomes were the inflammatory and stress responses measured by white blood cell count, neutrophil percentage, C-reactive protein (CRP), interleukin-6 (IL-6), and cortisol. Secondary outcomes were severity of pain and incidence of nausea and vomiting.
RESULTS: Sixty-four patients were enrolled and 59 patients completed the study. CRP, IL-6, and cortisol were significantly lower in the dexamethasone group compared with the control group during the 24 hours after UAE. Although the cumulative dose of fentanyl and additional analgesics administered during the 24 hours after UAE were similar between the two groups, pain scores were significantly lower in the dexamethasone group from 12 hours after UAE, and the incidence of severe nausea and vomiting was lower in the dexamethasone group.
CONCLUSIONS: The administration of single-dose intravenous dexamethasone as an adjunct to fentanyl-based intravenous PCA is effective in reducing inflammation and pain during the first 24 hours after UAE.
TWEETABLE ABSTRACT: Dexamethasone is effective in reducing inflammation and pain after uterine artery embolisation.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (29)
- Comparison of the efficacy of dexmedetomidine plus fentanyl patient-controlled analgesia with fentanyl patient-controlled analgesia for pain control in uterine artery embolization for symptomatic fibroid tumors or adenomyosis: a prospective, randomized study via openalex
- Uterine artery embolization for symptomatic adenomyosis: a new technical development of the 1-2-3 protocol and predictive factors of MR imaging affecting outcomes via openalex
- doi:10.1111/aas.12115 via openalex
- doi:10.2344/0003-3006-60.1.25 via openalex
- doi:10.1007/s00464-009-0670-5 via openalex
- doi:10.1016/s1051-0443(07)61586-3 via openalex
- doi:10.1007/s00464-012-2180-0 via openalex
- doi:10.1016/j.jvir.2007.11.021 via openalex
- doi:10.1016/j.ajog.2006.10.888 via openalex
- doi:10.5402/2012/985495 via openalex
- doi:10.1055/s-2003-37237 via openalex
- doi:10.1016/j.ejphar.2013.10.008 via openalex
- doi:10.1016/j.jvir.2011.03.013 via openalex
- doi:10.3390/ph3061729 via openalex
- doi:10.1007/s00270-008-9430-5 via openalex
- doi:10.1148/rg.326125514 via openalex
- doi:10.1213/ane.0b013e31826f0a0a via openalex
- W2398077174 via openalex
- W6712373769 via openalex
- doi:10.1093/bja/aes431 via openalex
- doi:10.1148/radiology.153.1.6473771 via openalex
- doi:10.1111/j.1471-0528.2006.00885.x via openalex
- doi:10.1093/bja/85.1.109 via openalex
- doi:10.1159/000090321 via openalex
- doi:10.3109/02841850903258033 via openalex
- doi:10.1097/01.rvi.0000094620.61428.9c via openalex
- doi:10.3390/ph3072291 via openalex
- doi:10.1093/bja/88.4.496 via openalex
- doi:10.1097/aln.0b013e3181ec642e via openalex
Cited by (6)
- Uterine artery embolization for the treatment of symptomatic adenomyosis: a systematic review 2026
- The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies 2026
- Update on Endovascular Therapy for Fibroids and Adenomyosis 2023
- The Advantages and Disadvantages of Uterine Artery Embolization in Women with Adenomyosis: What’s New? 2021
- Management of Postprocedural Uterine Artery Embolization Pain 2021
- Uterine Artery Embolization for Leiomyomas and Adenomyosis: A Pictorial Essay Based on Our Experience from 1300 Cases 2019
Source provenance
- europepmc
- last seen: 2026-10-10T06:11:15.153948+00:00
- openalex
- last seen: 2026-05-10T10:46:18.646890+00:00
- pubmed
- last seen: 2026-10-08T21:16:59.636582+00:00
License: CC0
· commercial use OK